Skip to main content
OpenTrials
Completed

NCT Number: NCT00687505

Safety Study of FP-1039 To Treat Cancer

The primary purpose of this study is to evaluate the safety and tolerability of FP-1039, a new biologic treatment for cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Advanced Cancer

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Karmanos Cancer Institute, Detroit, Michigan, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects with metastatic or locally advanced unresectable solid tumors for which standard curative or supportive measures do not exist or are no longer effective
  • Male or female 18 years of age or older

Exclusion criteria

  • Presence or history of melanoma
  • Primary brain tumor
  • Presence or history of glaucoma

Treatment and study plan

FP-1039

Drug

Intravenous weekly administration

Primary outcomes

  1. Safety and tolerability

    Time frame: 4 weeks

Sponsors and collaborators

Lead sponsor

Five Prime Therapeutics, Inc.

Industry

Collaborators

  • Parexel

Registry information

Official study title

A Phase 1, Open-Label, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of FP-1039 in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors

Important dates

Study start
2008
Primary completion
2011
Study completion
2011
First posted
May 30, 2008
Registry last updated
Dec 13, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.